Loading...
XBRU
OXUR
Market cap189kUSD
, Last price  
EUR
Name

Oxurion NV

Chart & performance

D1W1MN
XBRU:OXUR chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
492.79%
Rev. gr., 5y
-23.21%
Revenues
555k
+18,400.00%
3,243,0001,252,00030,421,0004,213,0006,175,0002,476,00075,083,000112,781,00013,776,00011,198,0007,104,0005,810,0005,320,0003,946,0002,078,0001,128,000595,000263,0003,000555,000
Net income
-4m
L
-10,134,000-15,967,00012,095,000-14,070,000-13,942,000-21,637,00030,415,00026,401,000-51,115,000-37,884,000-60,314,00022,788,000-38,474,000-51,827,000-28,012,000-29,158,000-31,685,000-18,969,000119,000-3,728,000
CFO
-2m
L-17.55%
-8,418,000-14,797,00011,957,000-12,098,000-16,842,000-19,564,00027,789,00025,710,000-46,579,000-27,793,000-20,309,00026,295,000-31,116,000-31,100,000-27,097,000-27,155,000-20,016,000-9,765,000-2,068,000-1,705,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1991 and headquartered in Leuven, Belgium, Oxurion NV operates as a biopharmaceutical company focused on innovating and commercializing medical solutions for various eye ailments globally. Its flagship product, JETREA, is approved for addressing vitreomacular adhesion and vitreomacular traction. The company's clinical pipeline includes THR-149, a plasma kallikrein inhibitor currently in Phase II development for diabetic macular edema (DME), and THR-687, an integrin antagonist also undergoing Phase II trials for DME. Oxurion maintains strategic collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company adopted its current name, Oxurion NV, in September 2018, having previously been known as ThromboGenics NV.

Key people

Charles De Bollardiere
Non-Executive Independent Chairman of the Board · since 2023
Pascal Ghoson
Chief Executive Officer, Chief Financial Officer, Executive Director - Permanent Representative of MARS SARL, Member of the Executive Committee · since 2023
Philippe Barbeaux
Chief Scientific Officer, Member of the Executive Committee · since 2024
Andy De Deene
Chief Development Officer, Member of the Executive Committee · since 2020
James Hartmann
Non-Executive Independent Director · since 2023
Nelly Souleymane
Non-Executive Independent Director · since 2025
URL
https://www.oxurion.com
IPO date
Jul 07, 2006
Employees
27
Domiciled in
BE
Incorporated in
BE
Headquarters & legal address
Gaston Geenslaan 1
Heverlee, VBR 3001
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT